Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Clinical evidence

OptimUM-02

86 evidence topics · 20 sources

Objective
Location and study date
Study status, dates, and number of sites in the ClinicalTrials.gov record
Study characteristicQuoted record
Overall status“Active, not recruiting”
Study start (actual)“2023-10-31”
Primary completion (estimated)“2027-01-15”
Study completion (estimated)“2028-01-15”
Sites“This study has 68 locations”
Last update posted“Last Update Posted 2026-02-17”
European Union dates in the EU trial record
FieldQuoted record
Start date in the European Union“2024-10-09”
Estimated recruitment start date“2024-07-01”
Estimated global end date“2027-12-31”
Study design
Multi-stage randomized open-label design in the ClinicalTrials.gov record

“This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).” (opens the source at this quote in a new tab)

“The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.” (opens the source at this quote in a new tab)

“The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.” (opens the source at this quote in a new tab)

“The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms to evaluate the primary endpoint of overall survival (OS).” (opens the source at this quote in a new tab)

Allocation, assignment model, and masking in the ClinicalTrials.gov record
Design characteristicQuoted record
Allocation“Randomized”
Interventional model“Sequential Assignment”
Masking“None (Open Label)”
Randomization ratios and stratification factors in the ASCO 2026 presentation
Study stageRandomization ratio shown in the study design figure
Phase 2a (darovasertib 300 mg BID plus crizotinib, darovasertib 200 mg BID plus crizotinib, investigator's choice)“2:2:1”
Phase 2b and phase 3 (darovasertib 300 mg BID plus crizotinib, investigator's choice)“2:1”
Crossover from the control arm

No evidence found.

Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11” (opens the source at this quote in a new tab)

“AEs from prior anti-cancer therapy that have not resolved to Grade ≤1” (opens the source at this quote in a new tab)

“Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids” (opens the source at this quote in a new tab)

“High risk of syncope or falls” (opens the source at this quote in a new tab)

“Active adrenal insufficiency, active colitis, or active inflammatory bowel disease” (opens the source at this quote in a new tab)

“History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids” (opens the source at this quote in a new tab)

“Active infection requiring systemic antibiotic therapy or active Hepatitis B/C” (opens the source at this quote in a new tab)

“Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug” (opens the source at this quote in a new tab)

“Females who are pregnant or breastfeeding” (opens the source at this quote in a new tab)

“History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies” (opens the source at this quote in a new tab)

“Contraindication for treatment with investigator's choice therapies as per applicable labelling” (opens the source at this quote in a new tab)

“History of stroke within the last 6 months of the first dose of study drug” (opens the source at this quote in a new tab)

“Impaired Cardiac function or clinically significant cardiac diseases, including angina pectoris or acute myocardial infarction <= 6 months prior to start of study treatment” (opens the source at this quote in a new tab)

Treatment
Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)
Investigator's choice treatment at baseline (stratification), n (%)Investigator's choice arm (N=103)
Ipilimumab + nivolumab“79 ( 76.7)”
Pembrolizumab or dacarbazine“24 ( 23.3)”
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
FDA guidance on progression-free survival as a regulatory endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 420 participants in the current ClinicalTrials.gov record
FieldQuoted record
Enrollment (estimated)“420”
Planned enrollment of 420 participants from record version 39, November 2024
Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024
Testing hierarchy and alpha allocation for secondary endpoints and overall survival

No evidence found.

Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, performance status, and LDH stratum (ASCO 2026 presentation)
CharacteristicDarovasertib plus crizotinib (N=210)Investigator's choice (N=103)
Age, mean (range), years“61.1 (22 - 85)”“61.5 (29 - 85)”
Female, n (%)“101 (48.1)”“52 (50.5)”
Race, White, n (%)“177 (84.3)”“83 (80.6)”
Race, non-White, n (%)“4 (1.9)”“4 (3.9)”
Race, not reported, n (%)“29 ( 13.8)”“16 ( 15.5)”
ECOG 0, n (%)“162 (77.1)”“87 (84.5)”
ECOG 1, n (%)“48 (22.9)”“16 (15.5)”
Stratification LDH at baseline (IRT), ≤ ULN, n (%)“120 (57.1)”“62 (60.2)”
Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%)“65 (31.0)”“29 (28.2)”
Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%)“25 (11.9)”“12 (11.7)”
Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)
CharacteristicDarovasertib plus crizotinib (N=210)Investigator's choice (N=103)
Time since first metastatic diagnosis, median (range), years“0.18 (0.0 – 8.1)”“0.19 (0.0 – 4.6)”
Size of largest metastatic lesion ≤ 3 cm, n (%)“119 ( 56.7)”“67 ( 65.0)”
Size of largest metastatic lesion 3.1 to 8.0 cm, n (%)“73 ( 34.8)”“31 ( 30.1)”
Size of largest metastatic lesion ≥ 8.1 cm, n (%)“18 ( 8.6)”“5 ( 4.9)”
Hepatic disease only, n (%)“127 ( 60.5)”“65 ( 63.1)”
Extrahepatic disease only, n (%)“11 ( 5.2)”“7 ( 6.8)”
Hepatic and extrahepatic disease, n (%)“72 ( 34.3)”“31 ( 30.1)”
Participants by age group and geographic region in the PFS subgroup figure (ASCO 2026 presentation)
SubgroupParticipants, darovasertib plus crizotinib and control
Age under 65 years“118, 64”
Age 65 years or older“92, 39”
Geographic region, USA“74, 36”
Geographic region, non-USA“136, 67”
Efficacy results
Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026
OutcomeBy blinded independent central reviewBy investigator assessment
Median PFS, darovasertib plus crizotinib, months (95% CI)“Darova + Criz: 6.9 (5.6, 8.3)”“Darova + Criz: 6.7 (5.6, 8.2)”
Median PFS, control, months (95% CI)“Control: 3.1 (1.8, 4.2)”“Control: 2.7 (1.7, 4.1)”
Hazard ratio (95% CI)“HR = 0.42 (0.30, 0.59)”“HR = 0.36 (0.26, 0.50)”
Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm
OutcomeBICR, darovasertib plus crizotinib (N=210)BICR, investigator's choice (N=103)Investigator, darovasertib plus crizotinib (N=210)Investigator, investigator's choice (N=103)
Complete or partial response, n (%)“78 (37.1)”“6 (5.8)”“83 (39.5)”“2 (1.9)”
Objective response rate, 95% CI“30.6, 44.1”“2.2, 12.3”“32.9, 46.5”“0.2, 6.8”
Objective response, odds ratio (95% CI)“10.8 (4.4, 26.4)”Reference“34.6 (8.1, 146.9)”Reference
Median duration of response, months (95% CI)“6.8 (5.5, 11.3)”“NE”“6.8 (4.8, 9.7)”“NE”
Complete response, partial response, or stable disease for at least 12 weeks, n (%)“154 (73.3)”“32 (31.1)”“156 (74.3)”“28 (27.2)”
Disease control rate, 95% CI“66.8, 79.2”“22.3, 40.9”“67.8, 80.1”“18.9, 36.8”
Disease control, odds ratio (95% CI)“7.7 (4.3, 13.5)”Reference“9.5 (5.3, 17.0)”Reference
Best overall response, n (%)BICR, darovasertib plus crizotinib (N=210)BICR, investigator's choice (N=103)Investigator, darovasertib plus crizotinib (N=210)Investigator, investigator's choice (N=103)
Complete response“5 (2.4)”“0”“0”“0”
Partial response“73 (34.8)”“6 (5.8)”“83 (39.5)”“2 (1.9)”
Stable disease“107 (51.0)”“43 (41.7)”“99 (47.1)”“39 (37.9)”
Progressive disease“13 (6.2)”“29 (28.2)”“15 (7.1)”“34 (33.0)”
Non-evaluable by RECIST“0”“1 (1.0)”“1 (0.5)”“4 (3.9)”
Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)
Subgroup (n, darovasertib plus crizotinib and control)ORR by BICR, darovasertib plus crizotinib (%)ORR by BICR, control (%)Median PFS by BICR, darovasertib plus crizotinib (months)Median PFS by BICR, control (months)
LDH normal (n=120, 62)“46.7”“8.1”“8.4”“4.2”
LDH above ULN and below 2x ULN (n=65, 29)“27.7”“3.4”“5.7”“1.8”
LDH 2x ULN or higher (n=25, 12)“16.0”“0”“3.1”“1.7”
Hepatic metastases (n=127, 65)“45.7”“3.1”“8.3”“2.9”
Extrahepatic metastases only (n=11, 7)“27.3”“0”“6.7”“8.3”
Hepatic and extrahepatic metastases (n=72, 31)“23.6”“12.9”“4.9”“2.8”
ECOG PS 0 (n=162, 87)“38.3”“5.8”“6.8”“3.1”
ECOG PS 1 (n=48, 16)“33.3”“6.3”“6.9”“3.1”
Largest lesion below 3 cm (n=119, 67)“42.9”“6.0”“8.3”“4.0”
Largest lesion 3 to 8 cm (n=73, 31)“34.3”“6.5”“5.6”“1.6”
Largest lesion 8 cm or larger (n=18, 5)“11.1”“0”“4.2”“1.7”
Control stratum ipilimumab plus nivolumab (n=158, 79)“37.3”“5.1”“6.9”“3.1”
Control stratum pembrolizumab or dacarbazine (n=52, 24)“36.5”“8.3”“5.8”“2.8”
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)
OutcomeDarovasertib plus crizotinib (N=239)Investigator's choice (N=100)
Any TRAE, n (%)“235 (98.3)”“89 (89.0)”
Grade 3 or 4 TRAE, n (%)“97 (40.6)”“37 (37.0)”
Grade 5 TRAE, n (%)“1 (0.4)”“1 (1.0)”
Treatment-related serious adverse event, n (%)“22 (9.2)”“25 (25.0)”
TRAE leading to withdrawal, row not naming a drug, n (%)“2 (0.8)”“5 (5.0)”
TRAE leading to darovasertib withdrawal, n (%)“6 (2.5)”Not applicable
TRAE leading to crizotinib withdrawal, n (%)“24 (10.0)”Not applicable
TRAE leading to investigator's choice withdrawal, n (%)Not applicable“19 (19.0)”
TRAE leading to darovasertib dose reduction, n (%)“56 (23.4)”Not applicable
TRAE leading to crizotinib dose reduction, n (%)“63 (26.4)”Not applicable
Most common TRAE of any grade (20% or more), darovasertib plus crizotinib armDarovasertib plus crizotinib (N=239), n (%)
Any TRAE“235 ( 98.3)”
Diarrhea“203 ( 84.9)”
Nausea“179 ( 74.9)”
Peripheral edema“160 ( 66.9)”
Vomiting“119 ( 49.8)”
Dermatitis acneiform“100 ( 41.8)”
Fatigue“94 ( 39.3)”
Hypotension“79 ( 33.1)”
Hypoalbuminemia, dysgeusia, and dizziness, each“61 ( 25.5)”
Decreased appetite“57 ( 23.8)”
Most common TRAE of any grade (20% or more), investigator's choice armInvestigator's choice (N=100), n (%)
Any TRAE“88 ( 88.0)”
Diarrhea“29 ( 29.0)”
Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each“25 ( 25.0)”
Pruritus“24 ( 24.0)”
Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib armDarovasertib plus crizotinib (N=239), n (%)
Any grade 3 or 4 adverse event“97 ( 40.6)”
Diarrhea“24 ( 10.0)”
Syncope“17 ( 7.1)”
Hypotension“9 ( 3.8)”
Nausea and peripheral edema, each“7 ( 2.9)”
Anemia“6 ( 2.5)”
Grade 3 or 4 TRAE (2% or more), investigator's choice armInvestigator's choice (N=100), n (%)
Any grade 3 or 4 adverse event“37 ( 37.0)”
Alanine aminotransferase increased and aspartate aminotransferase increased, each“7 ( 7.0)”
Diarrhea“6 ( 6.0)”
Hepatitis“5 ( 5.0)”
Colitis“4 ( 4.0)”
Lipase increased, autoimmune hepatitis, and amylase increased, each“3 ( 3.0)”
Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each“2 ( 2.0)”
Study limitations
Summary

OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.

The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.

The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.